CELC vs PBYI
CELC: Celcuity is developing gedatolisib, a comprehensive PI3K/AKT/mTOR pathway inhibitor in Phase 3 trials for hormone receptor-positive breast cancer and metastatic prostate cancer. PBYI: Biopharmaceutical company commercializing NERLYNX (neratinib), an irreversible HER2 tyrosine kinase inhibitor for HER2-positive breast cancer, and developing alisertib for multiple cancer indications.
Side-by-side fundamentals
| Metric | CELC | PBYI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $90.14 | $7.87 | |
| Market cap as of 2026-07-23 | $4.4B | $418M | |
| P/E as of 2026-07-23 | n/a | 17.14 | |
| PEG as of 2026-07-23 | -0.82 | n/a | |
| Net margin as of 2026-07-23 | n/a | +10.7% | |
| Gross margin as of 2026-07-23 | n/a | +74.5% | |
| Operating margin as of 2026-07-23 | n/a | +13.0% | |
| ROE as of 2026-07-23 | -244.6% | +20.4% | PBYI higher |
| ROA as of 2026-07-23 | -50.2% | +12.1% | PBYI higher |
| Debt / equity as of 2026-07-23 | 6.04 | 0.09 | PBYI lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -2.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +0.0% | |
| Beta as of 2026-07-23 | 0.20 | 1.24 | |
| 1-year return as of 2026-07-22 close | +546.6% | +126.8% | CELC higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.